A Phase III, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor 257305

Brief Summary

Type:
Bladder

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT04987203

Study #:
STUDY00149140

Start Date:
Feb 16, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04987203

View Complete Trial Details & Eligibility at ClinicalTrials.gov